“Our product was the first [...] to demonstrate superior pharmacokinetic and pharmacodynamic results […] clinically proven”. “You should start CBD dosing at 10mg/day, with a maximum of 30mg/day”. These are just some examples of quotes by ‘PhD cannabis experts’, yet, these quotes are highly questionable. In this presentation, you will learn why.<br/> <br/>We will cover the current status of our knowledge on cannabinoid pharmacokinetics and dosing in humans. We will discuss matters such as: what factors influence pharmacokinetic parameters, and what factors determine dosing? What are the most important gaps in pharmacokinetics and dosing knowledge and how these can be tackled?<br/> <br/>Being familiarized with the most important concepts, we will put a magnifying glass over published studies: we will discuss what happens when clinical pharmacology studies are designed and analyzed incorrectly. Finally, we will discuss best practices and give some real-life examples of how clinical pharmacology studies can be done successfully.

Best practices in studying cannabinoid pharmacokinetics and dosing

ACS Fall 2020 Virtual Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.